161 related articles for article (PubMed ID: 27445501)
1. A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period.
Fukaya M; Sato K; Yamada T; Sato M; Fujisawa S; Minaguchi S; Kimata H; Dozono H
Clin Cosmet Investig Dermatol; 2016; 9():151-8. PubMed ID: 27445501
[TBL] [Abstract][Full Text] [Related]
2. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
[TBL] [Abstract][Full Text] [Related]
4. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma.
Choi JY; Dawe R; Ibbotson S; Fleming C; Doney A; Foerster J
Br J Dermatol; 2020 Apr; 182(4):1017-1025. PubMed ID: 31257575
[TBL] [Abstract][Full Text] [Related]
6. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
Katoh N; Ohya Y; Murota H; Ikeda M; Hu X; Ikeda K; Liu J; Sasaki T; Chu AD; Teixeira HD; Saeki H
JAAD Int; 2022 Mar; 6():27-36. PubMed ID: 34988493
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC; Jaworski JC; Kaiser JD; Hebert AA
BMC Pediatr; 2016 Jun; 16():75. PubMed ID: 27267134
[TBL] [Abstract][Full Text] [Related]
9. Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial.
van Halewijn KF; Bohnen AM; van den Berg PJ; Pasmans SGMA; Bindels PJE; Elshout G
BMJ Open; 2019 Jun; 9(6):e027239. PubMed ID: 31221882
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis.
Pena J; Zameza PA; Pixley JN; Remitz A; Feldman SR
J Allergy Clin Immunol Pract; 2023 May; 11(5):1347-1359. PubMed ID: 36997119
[TBL] [Abstract][Full Text] [Related]
11. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
[TBL] [Abstract][Full Text] [Related]
12. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.
Weidinger S; Baurecht H; Schmitt J
Br J Dermatol; 2017 Oct; 177(4):999-1003. PubMed ID: 28868633
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
Thomson J; Wernham AGH; Williams HC
Br J Dermatol; 2018 Apr; 178(4):897-902. PubMed ID: 29315479
[TBL] [Abstract][Full Text] [Related]
14. Histological and Immunohistological Findings Using Anti-Cortisol Antibody in Atopic Dermatitis with Topical Steroid Addiction.
Fukaya M
Dermatol Ther (Heidelb); 2016 Mar; 6(1):39-46. PubMed ID: 26838582
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
16. Duration of topical therapy in the maintenance of atopic dermatitis remission in pediatric age.
Pecoraro L; Florile M; Piazza M; Comberiati P; Clemente M; Tadiotto E; Pietrobelli A; Piacentini G
Minerva Pediatr (Torino); 2021 Aug; 73(4):294-300. PubMed ID: 29968448
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL; Gooderham M; Wollenberg A; Weidinger S; Armstrong A; Soung J; Ferrucci S; Lima RG; Witte MM; Xu W; ElMaraghy H; Natalie CR; Pierce E; Blauvelt A;
JAMA Dermatol; 2023 Feb; 159(2):182-191. PubMed ID: 36630140
[TBL] [Abstract][Full Text] [Related]
18. The knowledge of issues associated with topical corticosteroids using in patients with atopic dermatitis.
Jaworek A; Szafraniec K; Pastuszczak M; Zalewski A; Wojas-Pelc A
Pol Merkur Lekarski; 2019 Jun; 46(276):243-247. PubMed ID: 31260432
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey.
Takahashi-Ando N; Jones MA; Fujisawa S; Hama R
Drug Healthc Patient Saf; 2015; 7():57-62. PubMed ID: 25897263
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
